This suggests that passive immunization with tau antibodies is often a practical therapeutic concentrate on and that the CSF level of p-tau262/356 or from the microtubule binding domain (MTBD) can serve as a handy biomarker of tau pathology to watch tau therapeutics in clinical trials.From the La Biennale di Venezia Web-site: “Her fantastical bod